HEMOSTIMULATING PROPERTIES OF THE CONJUGATES OF GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR WITH ALENDRONIC ACID

被引:0
|
作者
Shimina, G. G. [1 ]
Bateneva, A. V. [1 ]
Tsyplenkova, E. S. [1 ]
Gamaley, S. G. [1 ]
Esina, T. I. [1 ]
Volosnikova, E. A. [1 ]
Danilenko, E. D. [1 ]
机构
[1] Inst Med Biotechnol State Res Ctr Virol & Biotechn, Fed Serv Surveillance Consumer Rights Protect & Hu, Khimzavodskaya St, Berdsk 633004, Russia
来源
PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA | 2022年 / 10卷 / 05期
关键词
recombinant human granulocyte-macrophage colony-stimulating factor; alendronic acid; conjugate; hemostimulating activity; accumulation in bone tissue and bone marrow; GM-CSF; ANTITUMOR-ACTIVITY; BONE; BISPHOSPHONATE; THERAPY; METHOTREXATE; DISPOSITION; DELIVERY;
D O I
10.19163/2307-9266-2022-10-5-472-482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the work is to evaluate the hemostimulating activity of recombinant human granulocyte-macrophage colony -stimulating factor (rhGM-CSF) conjugates with alendronic acid (ALN) in the model of cytostatic myelosuppression and the dynamics of rhGM-CSF accumulation as a part of the conjugate in the bone tissue and bone marrow of mice.Materials and methods. The conjugates obtained by a solid-phase synthesis using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide or periodate oxidation, were used. A hemostimulating activity was evaluated in a model of a cytostatic myelosuppression induced by the administration of cyclophosphamide to CBA/Calac mice. RhGM-CSF preparations were injected subcutaneously for 4-5 days at the dose of 90 mu g/kg. After the injections cycle had been completed, the total leukocyte and segmented neutrophil counts were carried out in the blood samples, and the total karyocyte count was carried out in the bone marrow samples. The tissue distribution of rhGM-CSF preparations was assessed in outbred CD-1 mice after a single intravenous administration at the effective dose. The content of rhGM-CSF in blood, femoral tissue and bone marrow was determined by enzyme immunoassay.Results. RhGM-CSF conjugates with ALN have been shown to retain the ability of the original protein to increase the number of leukocytes, segmented blood neutrophils, and bone marrow karyocytes under the action of conjugates. The stimulation of the neutrophil production used to be observed at earlier times than in the case of rhGM-CSF. The increase in the total number of bone marrow cells after the introduction of all three conjugates was more pronounced compared to the original protein (by 34%). The increased hemostimulatory effect of the AEG conjugate was accompanied by a more intense accumulation of rhGM-CSF in the bone tissue and bone marrow of mice. The rhGM-CSF introduced into the conjugate was detected in the bone tissue for 24 h and it circulated in the bloodstream for a longer time compared to the original protein.Conclusion. The data obtained make it possible to conclude that further work on the development of effective hemostimulating drugs based on rhGM-CSF conjugates with ALN, is promising.
引用
收藏
页码:472 / 482
页数:11
相关论文
共 50 条
  • [31] Granulocyte-macrophage colony stimulating factor prior to chemotherapy for advanced epithelial ovarian cancer
    Guner, H
    Oktem, M
    Dilek, TUK
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2003, 83 (03) : 317 - 318
  • [32] POTENTIAL USES OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN CHILDREN
    FURMAN, WL
    CRIST, WM
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1991, 13 (04): : 388 - 399
  • [33] PEGylated murine Granulocyte-macrophage colony-stimulating factor: Production, purification, and characterization
    Sainathan, SK
    Tu, LW
    Bishnupuri, KS
    Han, M
    Li, AG
    Newberry, RD
    McDonald, KG
    Crimmins, DL
    Houchen, C
    Anant, S
    Dieckgraefe, BK
    PROTEIN EXPRESSION AND PURIFICATION, 2005, 44 (02) : 94 - 103
  • [34] A Promising Target in Rheumatoid Arthritis Treatment: Granulocyte-Macrophage Colony-Stimulating Factor
    A. Berkant Avci
    Eugen Feist
    Gerd-R. Burmester
    Current Treatment Options in Rheumatology, 2015, 1 (4) : 320 - 333
  • [35] Granulocyte-Macrophage Colony-Stimulating Factor Is Neuroprotective in Experimental Traumatic Brain Injury
    Shultz, Sandy R.
    Tan, Xin L.
    Wright, David K.
    Liu, Shijie J.
    Semple, Bridgette D.
    Johnston, Leigh
    Jones, Nigel C.
    Cook, Andrew D.
    Hamilton, John A.
    O'Brien, Terence J.
    JOURNAL OF NEUROTRAUMA, 2014, 31 (10) : 976 - 983
  • [36] FUTURE USES OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)
    JONES, TC
    STEM CELLS, 1994, 12 : 229 - 240
  • [37] Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain
    Cook, Andrew D.
    Pobjoy, Jarrad
    Sarros, Shannon
    Steidl, Stefan
    Duerr, Manuela
    Lacey, Derek C.
    Hamilton, John A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (02) : 265 - 270
  • [38] Myeloprotective effect of short term prechemotherapy recombinant granulocyte-macrophage colony stimulating factor
    Akyüz, C
    Çaglar, K
    Varan, A
    Koseoglu, V
    Canpinar, H
    Kutluk, T
    Büyükpamukçu, M
    MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (01): : 67 - 69
  • [39] Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma
    Kelso, Matthew L.
    Elliott, Bret R.
    Haverland, Nicole A.
    Mosley, R. Lee
    Gendelman, Howard E.
    JOURNAL OF NEUROIMMUNOLOGY, 2015, 278 : 162 - 173
  • [40] Establishment of human granulocyte-macrophage colony stimulating factor producing transgenic SCID mice
    Miyakawa, Y
    Fukuchi, Y
    Ito, M
    Kobayashi, K
    Kuramochi, T
    Ikeda, Y
    Takebe, Y
    Tanaka, T
    Miyasaka, M
    Nakahata, T
    Tamaoki, N
    Nomura, T
    Ueyama, Y
    Shimamura, K
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) : 437 - 442